Attenuating adaptive VEGF-A and IL-8 signaling restores durable tumor control in AR-antagonist-treated prostate cancers by Maxwell, PJ, McKechnie, M, Armstrong, CW, Manley, JM, Ong, CW, Worthington, J, Mills, IG, Longley, DB, Quigley, JP, Zoubedi, A, de Bono, JS, Deryugina, E, LaBonte, MJ, Waugh, DJJ

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer by Basu, B, Krebs, MG, Sundar, R, Wilson, RH, Spicer, J, Jones, R, Brada, M, Talbot, DC, Steele, N, Garces, AH, Brugger, W, Harrington, EA, Evans, J, Hall, E, Tovey, H, De Oliveira, FM, Carreira, S, Swales, K, Ruddle, R, Raynaud, FI, Purchase, B, Dawes, JC, Parmar, M, Turner, AJ, Tunariu, N, Banerjee, S, De Bono, JS, Banerji, U